TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.
Yu J, Fan Z, Zhou Z, Zhang P, Bai J, Li X, Tang M, Fan N, Wu X, Nie X, Chen X, Ma D, Chen X, Cui L, Xia X, Yang L, Yi X, Li L.
Yu J, et al.
Cancers (Basel). 2022 Jul 12;14(14):3382. doi: 10.3390/cancers14143382.
Cancers (Basel). 2022.
PMID: 35884443
Free PMC article.